Adult Surviving Sepis Campaign Guidelines (Hour-1 Bundle)
Children's Surviving Sepsis Campaign Guidelines
Adult ICU Liberation Guidelines and Bundle (A-F)
Management of Adults with COVID-19
New User? Sign Up Free
SCCM is updating its SCCM Connect Community. Access to SCCM Connect may be limited until April 23.
On Thursday, October 28, 2021, SCCM will be performing maintenance on our websites. Users may experience intermittent issues when trying to access some functionality of SCCM.org.
Severe Acute Respiratory Infection – Preparedness (SARI-PREP) aims to rapidly inform and improve clinical management of epidemic/pandemic SARI patients.
SARI-PREP is a multicenter consortium funded by the CDC Foundation. It is being assembled with the goal of providing the infrastructure to rapidly collect prospective data on clinical risks and outcomes, hospital-level stress, and biologic specimens that will aid in the rapid development of diagnostic and treatment approaches.
Specific causes of severe acute respiratory infection (SARI) to be targeted by SARI-PREP include SARS-CoV-2, influenza A and B viruses, and other known or novel viral infections causing outbreaks, epidemics, and pandemics of SARI.
The information gained will help to rapidly inform and improve clinical management of epidemic/pandemic SARI patients. The completion date is March 2022. The National Clinical Trial number is NCT04786301.
Society of Critical Care Medicine contacts: Adair Andrews RN, MATD, and Vishakha Kumar, MD, MBA
Identify the clinical characteristics and treatments associated with risk for severity of disease and important clinical outcomes in hospitalized patients at high risk for SARI due to respiratory viral illness caused by pathogens such as SARS-CoV-2 and influenza A and B viruses
Identify clinical characteristics and treatments differentiating patients with SARI due to specific respiratory viruses such as SARS-CoV-2 and influenza A among hospitalized patients with suspected viral SARI
Identify the molecular markers of risk for poor in-hospital and post-discharge clinical outcomes in hospitalized patients with viral SARI
Evaluate which patient characteristics and treatments are associated with organ failure-free days and mortality in patients with viral SARI
Report the natural history of a large cohort of patients with confirmed viral SARI
Central institutional review board (IRB) will be through the University of Nebraska. For additional IRB information, please contact SCCM staff.
At-risk cohort requires admission to an acute care or intensive care unit with a clinical syndrome of lower respiratory tract infection suspicious for viral SARI. This will be defined by the presence of fever, cough, and radiographic infiltrates by imaging (e.g., chest radiograph, CT) or Spo2 ≤ 94% on room air or requiring new supplemental oxygen (above baseline if preexisting) or requiring invasive or noninvasive mechanical ventilation.
Case cohort requires the criteria above plus confirmed viral cause for SARI by respiratory viral reverse transcription polymerase chain reaction testing.
Prisoners or wards of the state
Inability to consent or lack of availability of legal surrogate
Status of do-not-attempt resuscitation or do-not-intubate on admission
University of Washington Medical Center
Seattle, Washington, USA
Outcomes and published works from SARI-PREP.
Hospital Stress, Adaptation, and Resiliency During Respiratory Viral Acute Surge Events
Crit Connections. 2021 spring.
Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study. Crit Care. 2021;25:148.
Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome. Nat Microbiol. 2021;6:1245-1258.
Press releases and news articles highlighting SARI-PREP activities.
High Viral Load in Lungs Drives Fatal COVID-19: Study
U.S. News and World Report. August 31, 2021